Cannabidiol/Tetrahydrocannabivarin

N/A

Report date: 2025/04/25 15:08:12

Base Information

Drug NameCannabidiol/Tetrahydrocannabivarin
Drug Alias NameCannabidiol/delta-9-tetrahydrocannabivarinTHCV/CBDGW42004+GW42003GW42004/GW42003Tetrahydrocannabivarol-9+cannabidiol +[8] 
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsCannabinoid CB1 receptor antagonistsCannabinoid CB2 receptor inverse agonists
TargetsGlucagon-like peptide 1 receptorCannabinoid CB1 receptorCannabinoid CB2 receptor
Therapy Area/IndicationsDyslipidemiasDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsYes TetrahydrocannabivarinCannabidiol
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGw PharmaceuticalsUniversity Of Buckingham
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJazz Pharmaceuticals Plc
Active IndicationsN/A
Inactive IndicationsDyslipidemiasDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A